TOCILIZUMAB IMPACT ON BLOOD CHOLESTERINE TRANSPORT AND EARLY MANIFESTATION OF ATHEROSCLEROSIS IN PATIENTS WITH RHEUMATOID ARTHRITIS


Cite item

Full Text

Abstract

Aim. To evaluate tocilizumab (TLZ) effects on blood lipids composition and severity of carotid arteries (CA) atherosclerosis in rheumatoid arthritis (RA) patients after 24 week TLZ treatment. Material and methods. Before and 24 weeks after TLZ treatment 43 RA patients (33 women and 10 men) were examined by DAS 28 index, for blood serum concentration of cholesterol, triglycerides (TG), LPHD and LPLD cholesterol. The drug was injected intravenously in drops in a dose 8 mg/kg each 4 weeks. Results. A 24 week TLZ treatment produced satisfactory and good anti-inflammatory effects in RA patients. Hypoalphalipoproteinemia incidence and atherogenicity index (AI) reduced 3 and 5 times, respectively (p < 0.05). Elevated levels of cholesterol, TG, LDPL cholesterol occurred with the same frequency before and after TLZ treatment. Cholesterol rose by 11.6%, LPHD cholesterol by 48.9%, TG lowered by 7%, AI by 31.9% (p<0.05). LDLP cholesterol decreased. Blood lipids composition shifts were associated with marked reduction in the disease activity: decreased concentration of C-reactive protein, IgM rheumatoid factor, DAS28 index, improvement of the patient’s functional status. Maximal thickness of the intima-media complex of CA increased by 8.2%. Atherosclerotic plaques were revealed before and after treatment in 17 (41,4 %) patients from 41, in 5 (12,2%) patients the plaques arose after 6 months and in 5 (12,2%) patients the number of plaques increased. Conclusion. Because of both positive and negative effects of IL-6 receptor inhibitors on blood lipids, combined treatment of RA must include statins for correction of dyslipidemia.

About the authors

T V Popkova

Research Institute of Rheumatology of the Russian Academy of Medical Sciences

Email: popkovatv@mail.ru
д-р мед. наук, рук лаб. системных ревматических заболеваний с группой гемореологических нарушений НИИР РАМН

D S Novikova

Research Institute of Rheumatology of the Russian Academy of Medical Sciences

Email: Diananovikova75@yandex.ru
канд. мед. наук, ст. науч. сотр. лаб. функциональной и ультразвуковой диагностики НИИР РАМН

E Yu Panasyuk

Research Institute of Rheumatology of the Russian Academy of Medical Sciences

Email: panasyukelena@mail.ru
канд. мед. наук, ст. науч. сотр. лаб. клинических исследований и международных связей НИИР РАМН

A S Avdeeva

Research Institute of Rheumatology of the Russian Academy of Medical Sciences

Email: sokrat@irramn.ru
аспирант РИИР РАМН

E V Udachkina

Research Institute of Rheumatology of the Russian Academy of Medical Sciences

Email: sokrat@irramn.ru
врач-кардиолог РИИР РАМН

E N Alexandrova

Research Institute of Rheumatology of the Russian Academy of Medical Sciences

Email: irramn@rambler.ru
д-р мед. наук, рук. лаб. иммунологии и молекулярной биологии ревматических заболеваний НИИР РАМН

A A Novikov

Research Institute of Rheumatology of the Russian Academy of Medical Sciences

Email: irramn@rambler.ru
канд. биол. наук, вед. науч. сотр. лаб. иммунологии и молекулярной биологии ревматических заболеваний НИИР РАМН

A V Volkov

Research Institute of Rheumatology of the Russian Academy of Medical Sciences

канд. мед. наук, рук. лаб. функциональной и ультразвуковой диагностики НИИР РАМН

E L Nasonov

Research Institute of Rheumatology of the Russian Academy of Medical Sciences

Email: sokrat@irramn.ru
д-р мед. наук, проф., акад. РАМН, дир. НИИ ревматологии РАМН

References

  1. Насонов Е. Л., Каратеев Д. Е., Балабанова Р. М. Ревматоидный артрит. В кн.: Насонов Е. Л., Насонова В. А. (ред.). Ревматология: Нац. руководство. М.: ГЭОТАР-Медиа; 2008. 290—331.
  2. Попкова Т. В., Новикова Д. С., Насонов Е. Л. Атеросклероз при ревматических заболеваниях. В кн.: Ревматология: Клинические рекомендации. M.: ГЭОТАР-Медиа; 2010. 678—702.
  3. Peters M. J., Symmons D. P., McCarey D. W. et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other types of inflammatory arthritis — TASK FORCE "Cardiovascular risk management in RA". Ann. Rheum. Dis. 2010; 69 (2): 325—331.
  4. Meune C., Touze E., Trinqurte L. et al. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. Rheumatology,2009; 48 (10): 1309—1313.
  5. van Halm V. P., Voskuyl M. J. et al. Rheumatoid arthritis versus type 2 diabetes as a risk factor for cardiovascular disease: a cross-sectional study. Ann. Rheum. Dis. 2009; 68: 1395—1400.
  6. Nurmohamed M. T., Kitas G. Cardiovascular risk in rheumatoid arthritis and diabetes: how does it compare and when does it start? Ann. Rheum. Dis. 2011; 70(6): 881—883.
  7. Maradit Kremers H., Crowson C. S., Therneau T. M. et al. High ten-year risk of cardiovascular disease in newly diagnosed rheumatoid arthritis patients. A population-based cohort study. Arthr. and Rheum. 2008; 58 (8): 2268—2274.
  8. Goodson N. I., Willes N. J., Lunt N. C. Mortality on early inflammatory arthritis: cardiovascular mortality in seropositive patients. Arthr. and Rheum. 2002, 46: 2010—2019.
  9. Gonzalez-Gay M. A., Gonzalez-Juanatey C., Martin J. Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin. Arthr. Rheum. 2005; 35: 8—17.
  10. Gerli R., Bartoloni Bocci E., Sherer Y. et al. Association of anti-cyclic citrullinated peptide antibodies with subclinical atherosclerosis in patients with rheumatoid arthritis. Ann. Rheum. Dis. 2008; 67: 724—725.
  11. Lopez-Longo F. J., Oliver-Minarro D., de la Torre I. et al. Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthr. and Rheum. 2009; 61: 419—424.
  12. Leuven S. I., Franssen R., Kastelein J. J. et al. Systemic inflammation as a risk factor for atherothrombosis. Rheumatology 2008; 47: 3—7.
  13. Насонов Е. Л. Иммунологические маркеры атеросклероза. Тер. арх. 2002; 5: 80—85.
  14. Peterson M. J., Symmons D. P., McCarrey D. W. et al. Cardiovascular risk management in patients with rheumatoid arthritis and other types of inflammatory arthritis — EULAR TASK FORCE "Cardiovascular risk management in RA". Ann. Rheum. Dis. 2008; 67 Suppl II): 310.
  15. Насонов Е. Л. Фармакотерапия ревматоидного артрита — взгляд в 21 век. Клин. мед. 2005; 6: 8—12.
  16. Насонов Е. Л. Фармакотерапия ревматоидного артрита в эру генноинженерных биологических препаратов. Тер. арх. 2007; 5: 5—8.
  17. Smolen J. S., Aletaha D., Koeller M. et al. New therapies for treatment of rheumatoid arthritis. Lancet 2007; 370: 861—874.
  18. Ridker P. M., Rifai N., Stampfer M. J. et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101: 1767—1772.
  19. Насонов Е. Л. Иммунологические маркеры атеросклероза. В кн.: Антифосфолипидный синдром. М.: Литера; 2004. 278-298.
  20. Pearson T. A., Mensah G. A., Alexander R. W. et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499—511.
  21. Насонов Е. Л. Новые возможности фармакотерапии ревматических болезней — ингибирование интерлейкина 6. Клин. фарма-кол. и тер. 2008; 1: 2—8.
  22. Nishimoto N., Yoshizaki K., Miyasaka N. et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthr. and Rheum. 2004; 50: 1761—1769.
  23. Maini R. N., Taylor P. C., Szechinski J. et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthr. and Rheum. 2006; 54: 2817—2829.
  24. Nishimoto N., Hashimoto J., Miyasaka N. et al. Study ofActive Controlled Monotherapy Used for Rheumatoid Arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X-ray reader-blinded randomized controlled trial of tocilizumab. Ann. Rheum. Dis. 2007; 66: 1162—1167.
  25. Kawashiri Shin-ya, Kawakami Atsushi, Yamasaki Satoshi et al. Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis. Rheumatol. Int. 2011; 31 (4): 451—456.
  26. Nielen M. J., van Halm V. P., Nurmohamed M. T. et al. Rheumatoid arthritis is preceded by a preclinical phase, characterized by increased C-reactive protein levels and a more atherogenic lipid profile. Arthr. and Rheum. 2003; 48: 344.
  27. van Halm V. P., Nielen M. J., Nurmohamed M. T. et al. Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann. Rheum. Dis. 2007; 66 (2): 184—188.
  28. Choi E., Sattar N. Interpreting lipid levels in the context of highgrade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann. Rheum. Dis. 2009; 68 (4): 460—469.
  29. Arnett F. C., Edworthy S. M., Bloch D. A. The ARA 1987 revised criteria for classification of rheumatoid arthritis. Arthr. and Rheum. 1988; 31: 315—324.
  30. Насонов Е. Л., Насонова В. А. (ред.). Ревматология: Нац. руководство. М.: Гэотар-Медиа; 2008.
  31. Беленков Ю. Н., Оганов Р. Г. (ред.). Кардиология: Нац. руководство. М.: Гэотар-Медиа; 2007.
  32. Artiss J. D., Zak B. Measurement of cholesterol concentration. In: Rifai N., Warmic G. R., Dominiczak M. H., eds. Handbook of lipoprotein testing. Washington: AACC Press, 1997. 99-114.
  33. Friedwald W. T., Levy R. J., Fredrickson D. S. Estimation of the calculation of LDL cholesterol in plasma without use of the preparative ultracentrifuge. Clin. Chem. 1972; 18: 499—502.
  34. Nishimoto N., Miyasaka N., Yamamoto K. et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod. Rheumatol. 2009; 19: 12—19.
  35. Garnero P., Mareau E. E., Thompson E. et al. Relationships between changes in biological markers of inflammation and cartilage metabolism and radiological progression in patients with rheumatoid arthritis treated with tocilizumab combined with methotrexate: the LITHE study. Ann. Rheum. Dis. 2009; 68 (Suppl. 3): 547.
  36. Smolen J., Beaulieu M., Rubbert-Roth A. et al. Tocillizumab, a novel monoclonal antibody targeting IL-6 signalling, significantly reduces disease activity in patients with rheumatoid arthritis. Ann. Rheum. Dis. 2007; 66 (Suppl. II): 117.
  37. Genovese M. C., McKay J. D., Nasonov E. L. et al. Interleukin-6 receptor inhibition with tocillizumab reduced disease activity in patients with rheumatoid arthritis with inadequate response to diseasemodifying antirheumatic drug therapy study. Arthr. and Rheum. 2008; 58 (10): 2968—2980.
  38. Del Rincon I., Williams K., Stern M. P. et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthr. and Rheum. 2001; 44,:2737—2745.
  39. Dessein P. H., Joffe B. I., Veller M. G. et al. Traditional and nontradi-tional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. J. Rheumatol. 2005; 32: 435-442.
  40. Попкова Т. В., Новикова Д. С., Новиков А. А. и др. Роль нарушений в системе транспорта холестерина крови в развитии атеросклероза при ревматоидном артрите. Науч.-практ. ревматол. 2007; 5: 4—10.
  41. Sattar N., Crompton P., Cherry L. Effects oftumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: a double-blind, placebo-controlled study. Arthr. and Rheum. 2007; 56: 831—839.
  42. Khovidhunkit W., Memon R. A., Feingold K. R. et al. Infection and inflammation-induced proatherogenic changes of lipoproteins. J. Infect. Dis. 2000; 181 (Suppl. 3): 462—472.
  43. Burger D., Dayer J. M. High-density lipoprotein-associated apolipoprotein A-1: the missing link between infection and chronic inflammation? Autoimmun. Rev. 2002; 1: 111—117.
  44. Navab M., Berliner J. A., Subbanagounder G. et al. HDL and inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler. Thromb. Vasc. Biol. 2001; 2:, 481—488.
  45. McMahon M., Grossman J., FitzGerald J. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthr. and Rheum. 2006; 54 (8): 2541—2549.
  46. Ananth L., Prete P. E., Kashyap M. L. Apolipoproteins A-I and B and cholesterol in synovial fluid of patients with rheumatoid arthritis. Metabolism 1993; 42 (7): 803—806.
  47. Lourida E. S., Georgiadis A. N., Papavasiliou E. C. et al. Patients with early rheumatoid arthritis exhibit elevated autoantibody titers against mildly oxidized low-density lipoprotein and exhibit decreased activity of the lipoprotein-associated phospholipase A2. Arthr. Res. Ther. 2007; 9: 19.
  48. Dursunoglu D., Ervengul H., Polat B. et al. Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relationship to inflammation. Rheumatol. Int. 2005; 25 (4): 241—245.
  49. Park Y. B., Lee S. K., Suh C. H. et al. Lipid profiles in untreated patients with rheumatoid arthritis. J. Rheumatol. 1999; 26 (8): 1701—1704.
  50. Yoo W.-H. Dyslipoproteinemia in patients with active rheumatoid arthritis: effects of disease activity, sex, and menopausal status on lipid profiles. J. Rheumatol. 2004; 31: 1746—1753.
  51. Hulthe J., Fogerberg B. Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (AIR study). Arterioscler. Thromb. Vasc. Biol. 2002; 22: 1162—1167.
  52. Navab M., Hama S. Y., Anantharamaiah G. M. et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J. Lipid Res. 2000; 41: 1495—1508.
  53. Navab M., Hama S. Y., Cooke C. J. et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J. Lipid Res. 2000; 41: 1481—1494.
  54. Navab M., Hama-Levy S., Van Lenten B. J. et al. Mildly oxidised LDL induces an increased apolipoprotein J/paraoxonase ratio. J. Clin. Invest. 1997; 99: 2005—2019.
  55. Mackness M. I., Arrol S., Durrinton P. N. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 1991; 286: 152—154.
  56. Watson A. D., Navab M., Hama S. Y. et al. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J. Clin. Invest. 1995; 95: 774—782.
  57. Gomaraschi M., Basilico N., Sisto F. et al. High-density lipoproteins attenuate interleukin-6 production in endothelial cells exposed to proinflammatory stimuli. Biochim. Biophys. Acta 2005; 1736: 136—143.
  58. Choi E., Sattar N. Interpreting lipid levels in the contex of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann. Rheum. Dis. 2009; 68: 460—469.
  59. Khovidhunkit W., Kim M. S., Memon R. A. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J. Lipid Res. 2004; 45: 1169—1196.
  60. Российские рекомендации по диагностике и коррекции нарушений липидного обмена с целью профилактики и лечения атеросклероза. В кн.: Оганов Р. Г. (ред.). Национальные клинические рекомендации. Сборник. 2-е изд. М.: Силицея-Полиграф; 2009. 20—106.
  61. Woods A., Brull D. J., Humphries S. E. et al. Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6. Eur. Heart J. 2000; 21: 1574—1583.
  62. Popa C., Netea M. G., Radstake T. R.et al. Markers of inflammation are negatively correlated with serum leptin in rheumatoid arthritis. Ann. Rheum. Dis. 2005; 64: 303—305.
  63. Schimmel E. K., Yazici Y. Increased lipid levels but unchanged atherogenic index in rheumatoid arthritis patients treated with biologic disease modifying antirheumatic drugs: published experience. Clin. Exp. Rheumatol. 2009; 27: 446—451.
  64. Kerekes G., Soltesz P., Der H. Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis. Clin. Exp. Rheumatol. 2009; 28: 705—710.
  65. Попкова Т. В., Новикова Д. С., Линева О. Г. и др. Влияние ритуксимаба на систему транспорта холестерина крови у больных ревматоидным артритом. Науч.-практ. ревматол. 2010;4: 26-31.
  66. Saiki O., Takao R., Naruse Y. et al. Infliximab but not methotrexate induces extra-high levels of VLDL-triglyceride in patients with rheumatoid arthritis. J. Rheumatol. 2007; 34: 1997—2004.
  67. Nishimoto N., Yoshizaki K., Maeda K. et al. Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis: phase I/II clinical study. J. Rheumatol. 2003; 30: 1426—1435.
  68. Allanore Y., Kahan A., Sellam J. et al.: Effects of repeated infliximab therapy on serum lipid profile in patients with refractory rheumatoid arthritis. Clin. Chimic. Acta 2006; 365: 143—148.
  69. Popa C., Van Den Hoogen F. et al. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. Ann. Rheum. Dis. 2007; 66: 1503—1507.
  70. Irace C., Mancuso G., Fiaschi E. et al. Effect of anti TNF-alpha therapy on arterial diameter and wall shear stress and HDL cholesterol. Atherosclerosis 2004; 17: 113—118.
  71. Dahlqvist S., Engstrand S., Berglin E. et al. Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during longterm infliximab therapy. Scand. J. Rheumatol. 2006; 35: 107—114.
  72. Peters M., Van Halm V., Wolbink G. et al. Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis. Ann. Rheum. Dis. 2007; 66: 958—961.
  73. Spanakis E., Sidiropoulos P., Papadakis J. et al. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. J. Rheumatol. 2006; 33: 2440—2446.
  74. Tam K., Tomlinson B., Chu T. et al. Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clin. Rheumatol. 2007; 26: 1495—1498.
  75. Vis M., Nurmohamed M., Wolbink G. et al. Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. J. Rheumatol. 2005; 32: 252—255.
  76. Seriolo B., Paolino S., Sulli A. et al. Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis. Ann. N. Y. Acad. Sci. 2006; 1069: 414—419.
  77. Seriolo B., Paolino S., Ferrone C., Cutolo M. Effects of etanercept or infliximab treatment on lipid profile and insulin resistance in patients with refractory rheumatoid arthritis. Clin. Rheumatol. 2007; 26: 1799—1800.
  78. Popa C., Netea M. G., Radstake T. et al. Influence of anti-tumor necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann. Rheum. Dis. 2005; 64: 303—305.
  79. Gonzalez-Juanatey C., Llorca J., San-Chez Andrade A. et al. Shortterm adalimumab therapy improves endothelial function in patients with rheumatoid arthritis refractory to in?iximab. Clin. Exp. Rheumatol. 2006; 24: 309—312.
  80. Kerekes G., Soltesz P., Der H. et al. Effects of biologics on vascular function and atherosclerosis associated with rheumatoid arthritis. Ann. N. Y. Acad. Sci., 2009, 1173: 814—821.
  81. Kitas G. D., Gabriel S. E. Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. Ann. Rheum. Dis. 2011; 70: 8—14.
  82. Genovese M. C., Smolen J. S., Emery P. et al. Concomitant use of statins in tocilizumab-treated patients with rheumatoid arthritis with elevated low density lipoprotein cholesterol: analysis of five phase 3 clinical trials. In: Program and abstracts of the American College of Rheumatology (ACR) 2008 Annual Scientific Meeting, Oct. 24—29, 2008, San Francisco; 2008. Abstr. 1672.
  83. De Vera M. A., Choi H., Abrahamowicz M. et al. Statin discontinuation and risk of acute myocardial infarction in patients with rheumatoid arthritis: a population-based cohort study. Ann. Rheum. Dis. 2011; 70: 1020—1024.
  84. Новикова Д. С., Попкова Т. В., Насонов Е. Л. Снижение кардиоваскулярного риска при ревматоидном артрите: двойная польза статинов. Науч.-практ. ревматол. 2010; 6: 61—72.
  85. Lazzerini P. E., Lorenzini S., Selvi E. et al. Simvastatin inhibits cytokine production and nuclear factor-kB activation in interleukin 1b-stimulated synoviocytes from rheumatoid arthritis patients. Clin. Exp. Rheumatol. 2007; 25: 696—700.
  86. Yokota K., Mioyoshi F., Myazaki K. et al. High concentration simvastatin induces apoptosis in fibroblast-like synoviocytes from patients with rheumatoid arthritis. J. Rheumatol. 2008; 35: 193—200.

Copyright (c) 2012 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies